Ancora Heart, a company developing a novel device-based therapy to address heart failure, said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch Ventricular Restoration System. Currently being evaluated in the CORCINCH-HF pivotal clinical trial, the AccuCinch System is designed to provide a minimally invasive treatment option for patients who have symptomatic heart failure (HF) with reduced ejection fraction (HFrEF).
The AccuCinch System is a device-based therapy and a transcatheter procedure to treat the enlarged left ventricle.
“The chronic and progressive nature of heart failure leaves many patients to face an increasingly challenging future as existing treatments, including medications and pacemaker devices, are not able to keep the disease at bay,” said Ulrich P. Jorde, MD, professor of medicine, Albert Einstein College of Medicine, and section head of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support at Montefiore Health System in New York, and global co-principal investigator of the CORCINCH-HF Study. “Early data on the AccuCinch System are promising, providing hope that this novel transcatheter approach may address the therapeutic gap for heart failure patients in the future.”
An estimated 6.5 million U.S. adults live with heart failure, a condition in which the heart’s muscles weaken and lose their ability to pump enough oxygen-rich blood to the body. Heart failure patients suffer from debilitating symptoms including persistent exhaustion, trouble breathing, leg swelling, and confusion. About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency. About 50 percent of people who develop heart failure die within five years of diagnosis.
“Ancora Heart is dedicated to developing solutions that address the unmet need for improved treatment options for heart failure patients,” said Jeff Closs, president and CEO of Ancora Heart. “The Breakthrough Designation is a valuable step in the pathway to FDA approval and we look forward to continuing to work closely with the agency in order to make the AccuCinch System available to these patients.”
